phData, Inc : phData Featured at Snowflake Summit 2023 as an Elite Partner finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
YPF y su Fundación entregaron 584 notebooks para estudiantes de escuelas técnicas secundarias lanoticia1.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lanoticia1.com Daily Mail and Mail on Sunday newspapers.
Published: May 11, 2021
- Enrollment Now Underway in Multiple Solid Tumor and Hematologic Malignancy Expansion Cohorts in Phase 1 Trial of Oral PRMT5 Inhibitor PRT543 -
- Initial Clinical Data Readouts for Lead Oral PRMT5 Inhibitors PRT543 and PRT811 Expected in 2H21 -
- Dose Escalation Ongoing in Phase 1 Trial of Oral MCL1 Inhibitor PRT1419, with Dose Expansion Cohorts on Track to be Added in 2H21 -
WILMINGTON, Del., May 11, 2021 (GLOBE NEWSWIRE) Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced its financial results for the first quarter ended March 31, 2021 and provided an update on recent clinical and development pipeline progress.